Careful examination (GSE67806) showed that the expression levels of genes upstream (Atoh7, Pbld1, Pbld2, Nnrnph3, Dna2, Slc25a16, Tet1, Snord98, Ccar1, Stox1, Ddx50, Ddx21) or downstream (Vps26a, Supv3I1, Hk1, Tacr2, Tspan15, Neurog3, Col13a1) of serglycin did not differ significantly between SG+/- and SG-/- tumours, indicating that heterozygotes are appropriate as controls. The gene discussed is SLC25A16; the disease is neoplasm.